Physician
Las Cruces Physician Services LLC
Las Cruces Physician Services LLC was paid $62.87M by Medicaid between Jan 2018 and Dec 2024, across 304 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 35% of everything it billed.
33Billing provider infoLAS CRUCES PHYSICIAN SERVICES LLC
LAS CRUCES, NM 88011
LAS CRUCES, NM 88011
33aNPI1215079678assigned 02/13/2007
33bProvider typeNeurological Surgery Physician
28Total paid$62.87M
24GClaims1,724,816
24DCodes billed304
24AFirst – last monthJan 2018 – Dec 2024
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official JACKSON, JENNIFER controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 241,909 | $8.16M | |
| 2019 | 200,781 | $9.11M | |
| 2020 | 183,291 | $8.70M | |
| 2021 | 328,728 | $9.75M | |
| 2022 | 322,525 | $9.79M | |
| 2023 | 252,557 | $8.46M | |
| 2024incomplete | 195,025 | $8.90M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 35% | 364,913 | 346,771 | $22.12M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 20% | 145,356 | 139,475 | $12.40M |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 4.5% | 34,391 | 34,096 | $2.82M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 4.2% | 26,099 | 22,975 | $2.65M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 3.4% | 19,900 | 19,872 | $2.13M |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 2.3% | 10,802 | 10,685 | $1.43M |
| 76819 | Fetal biophysical profile; without non-stress testing | 2.1% | 10,935 | 9,025 | $1.34M |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 2.1% | 12,037 | 12,019 | $1.29M |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 1.7% | 26,993 | 25,122 | $1.07M |
| 76820 | 1.7% | 10,243 | 8,478 | $1.05M | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 1.6% | 9,251 | 8,896 | $977K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.5% | 56,860 | 56,166 | $929K |
292 more codes
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | 1.4% | 8,570 | $901K |
| 76801 | 1.2% | 6,109 | $784K | |
| 90461 | 1.2% | 13,425 | $726K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 1.0% | 28,723 | $632K |
| 59400 | Routine obstetric care including antepartum care, vaginal delivery, and postpartum care | <1% | 270 | $517K |
| 87428 | <1% | 6,589 | $480K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 25,986 | $426K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 10,968 | $422K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 3,832 | $408K |
| S9999 | Sales tax | <1% | 53,513 | $397K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 23,249 | $390K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 9,567 | $349K |
| 99173 | <1% | 9,410 | $319K | |
| 99460 | <1% | 3,688 | $286K | |
| 76830 | Ultrasound, transvaginal | <1% | 3,900 | $284K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 4,152 | $271K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 5,020 | $270K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 4,890 | $250K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 4,063 | $196K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,154 | $183K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,042 | $179K |
| 92551 | <1% | 14,777 | $175K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 4,430 | $165K |
| 95886 | <1% | 1,281 | $136K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 1,237 | $132K |
| 98926 | <1% | 3,196 | $122K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 1,474 | $122K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 2,020 | $113K |
| 99205 | Prolong outpt/office vis | <1% | 500 | $106K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 14,551 | $93K |
| 99442 | <1% | 1,098 | $93K | |
| 95811 | <1% | 877 | $93K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 767 | $84K |
| 20610 | <1% | 1,841 | $84K | |
| 99223 | Prolong inpt eval add15 m | <1% | 502 | $81K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,696 | $80K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 1,398 | $78K |
| 98927 | <1% | 1,574 | $75K | |
| 93000 | <1% | 6,227 | $70K | |
| 73130 | <1% | 2,820 | $70K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 743 | $69K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,940 | $65K |
| 59025 | Fetal non-stress test | <1% | 1,855 | $63K |
| 73110 | <1% | 2,454 | $63K | |
| 81025 | <1% | 6,802 | $57K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 1,320 | $54K |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 634 | $52K |
| 36415 | Collection of venous blood by venipuncture | <1% | 13,958 | $49K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,201 | $46K |
| 90474 | <1% | 2,023 | $45K | |
| 90686 | <1% | 12,824 | $40K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,076 | $39K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,279 | $39K |
| 90715 | <1% | 1,126 | $37K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 901 | $37K |
| 29075 | <1% | 463 | $34K | |
| 99051 | <1% | 1,026 | $33K | |
| 31231 | <1% | 231 | $33K | |
| 99385 | <1% | 185 | $32K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 325 | $31K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 275 | $31K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,823 | $30K |
| 17110 | <1% | 354 | $29K | |
| 73610 | <1% | 1,100 | $28K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,413 | $28K |
| 95806 | <1% | 467 | $28K | |
| 73630 | <1% | 1,084 | $28K | |
| 71045 | Radiologic examination, chest; single view | <1% | 3,634 | $27K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 411 | $26K |
| 76813 | <1% | 316 | $24K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 91 | $23K |
| 99441 | <1% | 504 | $23K | |
| 95909 | <1% | 191 | $21K | |
| 76641 | <1% | 500 | $21K | |
| 47562 | <1% | 37 | $21K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,178 | $21K |
| 20550 | <1% | 456 | $20K | |
| 99381 | <1% | 134 | $20K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 765 | $20K |
| 73564 | <1% | 724 | $20K | |
| 73140 | <1% | 938 | $19K | |
| 72100 | <1% | 1,122 | $19K | |
| 83655 | <1% | 1,433 | $19K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 272 | $18K |
| 73562 | <1% | 1,155 | $18K | |
| 43775 | <1% | 25 | $17K | |
| 90688 | <1% | 1,384 | $17K | |
| 73030 | <1% | 938 | $14K | |
| 29848 | <1% | 44 | $14K | |
| 99080 | <1% | 2,619 | $13K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 214 | $13K |
| 80050 | General health panel | <1% | 275 | $13K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 322 | $13K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 322 | $13K |
| 85018 | <1% | 5,057 | $13K | |
| 64483 | <1% | 66 | $13K | |
| 90473 | <1% | 558 | $12K | |
| 72110 | <1% | 372 | $12K | |
| 92558 | <1% | 416 | $12K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 154 | $11K |
| 76536 | <1% | 316 | $11K | |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 12 | $11K |
| 81002 | <1% | 4,129 | $10K | |
| 87807 | <1% | 694 | $10K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 1,102 | $10K |
| 82962 | <1% | 3,647 | $9K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 51 | $9K |
| 90480 | <1% | 215 | $8K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 43 | $8K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 2,302 | $8K |
| 98967 | <1% | 299 | $7K | |
| 93016 | <1% | 427 | $7K | |
| 71250 | <1% | 207 | $7K | |
| 64718 | <1% | 14 | $6K | |
| 80053 | Comprehensive metabolic panel | <1% | 506 | $6K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 139 | $6K |
| 99152 | <1% | 339 | $6K | |
| 0071A | <1% | 136 | $6K | |
| 80061 | Lipid panel | <1% | 353 | $5K |
| 93018 | <1% | 450 | $5K | |
| 49083 | <1% | 35 | $5K | |
| 99072 | <1% | 358 | $5K | |
| 93307 | <1% | 120 | $5K | |
| 81003 | <1% | 3,087 | $5K | |
| 58300 | <1% | 26 | $5K | |
| 99383 | <1% | 24 | $5K | |
| 95911 | <1% | 24 | $4K | |
| 99463 | <1% | 45 | $4K | |
| 81000 | <1% | 1,136 | $4K | |
| 74018 | <1% | 515 | $4K | |
| 93225 | <1% | 201 | $4K | |
| 93227 | <1% | 198 | $4K | |
| 98925 | <1% | 138 | $4K | |
| 84439 | <1% | 347 | $3K | |
| 92587 | <1% | 172 | $3K | |
| 96112 | <1% | 25 | $3K | |
| 90658 | <1% | 332 | $3K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 27 | $3K |
| 76770 | <1% | 88 | $3K | |
| 54160 | <1% | 13 | $3K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 52 | $3K |
| 84703 | <1% | 305 | $3K | |
| 43235 | <1% | 30 | $3K | |
| 93970 | <1% | 94 | $2K | |
| 93971 | <1% | 126 | $2K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 111 | $2K |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 68 | $2K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 68 | $2K |
| 86140 | <1% | 334 | $2K | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 188 | $2K |
| 98928 | <1% | 32 | $2K | |
| 87210 | <1% | 352 | $2K | |
| 82565 | <1% | 326 | $2K | |
| 90670 | <1% | 12,671 | $2K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 317 | $2K |
| 31575 | <1% | 25 | $2K | |
| 54150 | <1% | 12 | $2K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 13 | $2K |
| 73221 | <1% | 26 | $2K | |
| 99253 | <1% | 13 | $2K | |
| 85014 | <1% | 565 | $2K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 25 | $2K |
| 84460 | <1% | 241 | $1K | |
| 84450 | <1% | 239 | $1K | |
| 73502 | <1% | 117 | $1K | |
| 94727 | <1% | 145 | $1K | |
| 0072A | <1% | 32 | $1K | |
| 64721 | <1% | 12 | $1K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 12 | $1K |
| 59899 | <1% | 15 | $1K | |
| 72040 | <1% | 125 | $1K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 15 | $1K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 105 | $1K |
| 73070 | <1% | 46 | $1K | |
| 90647 | <1% | 8,549 | $1K | |
| 90656 | <1% | 208 | $1K | |
| 69210 | <1% | 28 | $1K | |
| 94060 | <1% | 100 | $1K | |
| 85651 | <1% | 248 | $999.53 | |
| 11102 | <1% | 12 | $990.43 | |
| 77080 | <1% | 76 | $986.56 | |
| 46600 | <1% | 13 | $883.40 | |
| 94729 | <1% | 133 | $876.57 | |
| 76818 | <1% | 15 | $874.93 | |
| 76857 | <1% | 42 | $867.63 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 13 | $756.16 |
| 94618 | <1% | 41 | $695.70 | |
| 93015 | <1% | 14 | $695.33 | |
| 90677 | <1% | 644 | $648.90 | |
| 1036F | <1% | 111,725 | $582.02 | |
| 78227 | <1% | 13 | $553.11 | |
| 99454 | <1% | 132 | $550.45 | |
| 96127 | <1% | 100 | $511.12 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 125 | $504.32 |
| 80076 | <1% | 47 | $475.70 | |
| 90680 | <1% | 7,824 | $468.75 | |
| 73560 | <1% | 42 | $452.40 | |
| 82948 | <1% | 88 | $447.24 | |
| 87088 | <1% | 41 | $402.25 | |
| 99308 | Subsequent nursing facility care, per day, straightforward | <1% | 12 | $397.20 |
| 72050 | <1% | 12 | $396.73 | |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | <1% | 27 | $364.68 |
| 73080 | <1% | 39 | $332.02 | |
| 93272 | <1% | 15 | $319.09 | |
| 3008F | <1% | 167,200 | $312.81 | |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | <1% | 13 | $311.39 |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 14 | $299.86 |
| 1160F | <1% | 29,155 | $291.00 | |
| 96380 | <1% | 13 | $289.98 | |
| 83721 | <1% | 30 | $286.60 | |
| 92552 | <1% | 16 | $285.58 | |
| 80305 | <1% | 21 | $277.84 | |
| 73020 | <1% | 15 | $271.89 | |
| 85610 | <1% | 56 | $259.13 | |
| 76000 | <1% | 38 | $254.02 | |
| 11045 | <1% | 14 | $233.74 | |
| 87420 | <1% | 16 | $225.19 | |
| 87280 | <1% | 16 | $217.03 | |
| 90698 | <1% | 807 | $200.82 | |
| 90651 | <1% | 1,145 | $191.65 | |
| 99406 | <1% | 15 | $188.12 | |
| 87070 | <1% | 15 | $167.65 | |
| 74022 | <1% | 14 | $160.62 | |
| 96160 | <1% | 29 | $130.98 | |
| 72070 | <1% | 12 | $127.25 | |
| 76937 | <1% | 18 | $124.77 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 12 | $121.82 |
| 90633 | <1% | 4,882 | $111.57 | |
| 99000 | <1% | 61 | $87.70 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 19 | $83.08 |
| 77001 | <1% | 14 | $82.16 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 13 | $80.36 |
| 90723 | <1% | 4,830 | $49.85 | |
| 90685 | <1% | 834 | $46.96 | |
| 90756 | <1% | 66 | $30.00 | |
| 90672 | <1% | 256 | $26.88 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 12 | $25.14 |
| 90687 | <1% | 400 | $20.87 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 12 | $15.40 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 39 | $5.30 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 13 | $2.50 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 15 | $1.10 |
| 0502F | <1% | 17,481 | $0.10 | |
| 3044F | <1% | 14 | $0.01 | |
| 3078F | 0% | 52,164 | $0.00 | |
| 3725F | 0% | 10,839 | $0.00 | |
| 1159F | 0% | 21,942 | $0.00 | |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 2,921 | $0.00 |
| 3077F | 0% | 4,343 | $0.00 | |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 1,914 | $0.00 |
| 90707 | 0% | 520 | $0.00 | |
| 90734 | 0% | 546 | $0.00 | |
| 90700 | 0% | 510 | $0.00 | |
| 90710 | 0% | 371 | $0.00 | |
| 90671 | 0% | 568 | $0.00 | |
| 90681 | 0% | 254 | $0.00 | |
| 90661 | 0% | 212 | $0.00 | |
| 91321 | 0% | 54 | $0.00 | |
| G9622 | Patient not identified as an unhealthy alcohol user when screened for unhealthy alcohol use using a systematic screening method | 0% | 58 | $0.00 |
| G8431 | Screening for depression is documented as being positive and a follow-up plan is documented | 0% | 272 | $0.00 |
| 4004F | 0% | 136 | $0.00 | |
| 90648 | 0% | 216 | $0.00 | |
| 90621 | 0% | 13 | $0.00 | |
| 3074F | 0% | 63,067 | $0.00 | |
| 1034F | 0% | 4,802 | $0.00 | |
| 1126F | 0% | 9,317 | $0.00 | |
| 3075F | 0% | 6,822 | $0.00 | |
| 3079F | 0% | 22,409 | $0.00 | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 0% | 3,406 | $0.00 |
| 91307 | 0% | 398 | $0.00 | |
| 0500F | 0% | 189 | $0.00 | |
| 3080F | 0% | 1,092 | $0.00 | |
| 1125F | 0% | 7,023 | $0.00 | |
| 90696 | 0% | 224 | $0.00 | |
| 90660 | 0% | 357 | $0.00 | |
| 2001F | 0% | 119 | $0.00 | |
| 1123F | 0% | 245 | $0.00 | |
| 90716 | 0% | 596 | $0.00 | |
| 3017F | 0% | 108 | $0.00 | |
| 90657 | 0% | 169 | $0.00 | |
| 90697 | 0% | 350 | $0.00 | |
| 90744 | 0% | 30 | $0.00 | |
| 99024 | 0% | 20 | $0.00 | |
| 2000F | 0% | 120 | $0.00 | |
| G8419 | Bmi documented outside normal parameters, no follow-up plan documented, no reason given | 0% | 39 | $0.00 |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 85 | $0.00 |
| 0501F | 0% | 37 | $0.00 | |
| 94760 | 0% | 13 | $0.00 | |
| G9275 | Documentation that patient is a current non-tobacco user | 0% | 14 | $0.00 |
| 1170F | 0% | 39 | $0.00 | |
| 0503F | 0% | 12 | $0.00 | |
| 3048F | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJACKSON, JENNIFER (SENIOR DIRECTOR, ENROLLMENT)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.